Degussa sells Proligo nucleic acid Group to Sigma-Aldrich
Degussa AG has sold the Proligo Group to Sigma-Aldrich Corporation for an undisclosed purchase price. Completion of the transaction remains subject to the approval of the German Federal Anti-Trust Office (Bundeskartellamt).
Annual sales at Proligo, which employs around 300 staff worldwide, totaled 30.9 million euros in 2004. Proligo operates in the field of nucleic acids and oligonucleotide synthesis, with sites in Hamburg, Paris, Boulder, Singapore, Kyoto and Lismore/Australia.
Ranking sixth in the oligonucleotides market Proligo does not have the opportunities to achieve a leading position through its own resources. Moreover, this market is expected to face heavy consolidation. As a result, Degussa has been evaluating strategic options for Proligo over the past few months.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.